2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-177277
    HM5023507 1549766-06-4
    HM5023507 is an orally active and selective PI3Kδ/γ inhibitor with IC50s of 4  and 5  μM for PI3Kδ and PI3Kγ over PI3Kβ and PI3Kα. HM5023507 attenuates the PI3Kδ/γ signaling in human basophils. HM5023507 also attenuates the activation and function of human B and T cells and cytokine and IgG production during cocultures, and Th17 differentiation of CD4 T cells. HM5023507 inhibited semiestablished collagen-induced arthritic inflammation in the rat models. HM5023507 can be used for inflammatory diseases like rheumatoid arthritis research.
    HM5023507
  • HY-177279
    RAF-IN-2 258851-00-2 98%
    RAF-IN-2 is a RAF inhibitor. RAF-IN-2 can be used for proliferative diseases such as leukemia, psoriasis and fibrosis research.
    RAF-IN-2
  • HY-177281
    IL-6-IN-3 601513-04-6
    IL-6-IN-3 (Example 4) is an IL-6 inhibitor with an IC50 of 0.4 nM. IL-6-IN-3 can be used for cancers like prostate cancer and arthritis like rheumatoid arthritis research.
    IL-6-IN-3
  • HY-177284
    Steroid sulfatase-IN-10 910231-67-3 98%
    Steroid sulfatase-IN-10 (Example 216) is a Steroid sulfatase inhibitor with an IC50 of 0.03-0.27 µM . Steroid sulfatase-IN-10 can be used for inflammatory diseases such as rheumatoid arthritis, type 1 and 2 diabetes and systemic lupus erythematosus research.
    Steroid sulfatase-IN-10
  • HY-177286
    c-Kit-IN-11 1185279-55-3
    c-Kit-IN-11 (Compound A7) is a c-Kit inhibitor with an IC50 of 76  nM for Mo7e cells. c-Kit-IN-11 can be used for inflammatory like asthma and malignant cancers research.
    c-Kit-IN-11
  • HY-177287
    c-Kit-IN-10 1123512-36-6
    c-Kit-IN-10 (Compound 1) is a c-Kit inhibitor. c-Kit-IN-10 can be used for inflammatory like asthma and malignant cancers research.
    c-Kit-IN-10
  • HY-177304
    Anti-inflammatory agent 104 382630-23-1 98%
    Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. The IC50 of Anti-inflammatory agent 104 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.024 nM. Anti-inflammatory agent 104 can reduce eosinophils in rat lungs by 63%.
    Anti-inflammatory agent 104
  • HY-177305
    Anti-inflammatory agent 105 382630-14-0 98%
    Anti-inflammatory agent 105 (Compound 12) is an anti-inflammatory compound. The IC50 of Anti-inflammatory agent 105 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.124 nM.
    Anti-inflammatory agent 105
  • HY-177312
    CCR3 antagonist 2 606128-24-9
    CCR3 antagonist 2 (example 66) is a CCR3 antagonist that can be used for the study of inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
    CCR3 antagonist 2
  • HY-177315
    Cathepsin K-IN-8 501126-27-8
    Cathepsin K-IN-8 (cxample 6-60) is a cathepsin K inhibitor that can be used for the study of inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Cathepsin K-IN-8
  • HY-177318
    αLβ2 integrin-IN-1 579526-88-8
    αLβ2 integrin-IN-1 (example 1) is an αLβ2 integrin mediated cell adhesion inhibitor that can be used for the study of αLβ2 integrin mediated inflammatory conditions.
    αLβ2 integrin-IN-1
  • HY-177319
    COX-2-IN-56 1000590-53-3 98%
    COX-2-IN-56 (example 6) is a selective COX-2 inhibitor without significantly inhibiting COX-1. COX-2-IN-56 can be used for the study of COX-2 dependent disorders, such as inflammation.
    COX-2-IN-56
  • HY-177320
    p38 Kinase-IN-9 836682-64-5 98%
    p38 Kinase-IN-9 (example 4) is a p38 kinase inhibitor with an IC50 of <1 μM. p38 Kinase-IN-9 can be used for the study of p38 kinase mediated diseases, including inflammatory diseases.
    p38 Kinase-IN-9
  • HY-177338
    STING agonist-45 2361424-97-5
    STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8+ T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases.
    STING agonist-45
  • HY-177388
    Factor B-IN-6 2797066-55-6 98%
    Factor B-IN-6 is an orally active Factor B inhibitor. Factor B-IN-6 exhibits significant inhibitory activity against activation of the human serum serotonin pathway. Factor B-IN-6 can improve the severity of renal lesions and renal function, and reduce urinary protein in animal models. Factor B-IN-6 is useful for kidney disease research.
    Factor B-IN-6
  • HY-177414
    BB-1701 98%
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune.
    BB-1701
  • HY-177433
    NLRP3 modulator 8 3069891-88-6 98%
    NLRP3 modulator 8 (Compound 14) is a NLRP3 modulator. NLRP3 modulator 8 significantly degrades NEK7 with an DC50 of 9  nM. NLRP3 modulator 8 dose-dependently inhibits caspase-1 activity and IL-1β release in macrophages in response to NLRP3 inflammasome activation. NLRP3 modulator 8 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
    NLRP3 modulator 8
  • HY-177456
    STAT6 degrader-3 3077464-19-5
    STAT6 degrader-3 (I-1) is a STAT6 degrader with a DC50 of <1 nM.
    STAT6 degrader-3
  • HY-177515
    IRAK4 modulator-2 1356013-27-8 99.86%
    IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1 inhibitor with IC50 values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease.
    IRAK4 modulator-2
  • HY-177559
    NEK7 degrader-2 3037413-54-7
    NEK7 degrader-2 (Compound 25) is a NEK7 degrader. NEK7 degrader-2 shows dose-dependent NEK7 degradation ability in human PBMC-derived macrophages. NEK7 degrader-2 reduce the release level of pro-inflammatory cytokines IL-1β induced by NLRP3 inflammasome activation. NEK7 degrader-2 can be used for the study of inflammatory diseases.
    NEK7 degrader-2
Cat. No. Product Name / Synonyms Application Reactivity